NCT00166322View on ClinicalTrials.gov

Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions
Schizophrenia
Interventions
PROCEDURE

IBZM-SPECT (bolus and constant infusion paradigm)

single IBZM-SPECT assessment at study inclusion

Trial Locations (2)

D-80336

Dept. of Psychiatry, Munich

D-81377

Dept. of Nuclear Medicine, Munich

All Listed Sponsors
lead

Ludwig-Maximilians - University of Munich

OTHER

NCT00166322 - Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects | Biotech Hunter | Biotech Hunter